ARTICLE | Clinical News
GGTI-2418: Phase I start
March 9, 2009 7:00 AM UTC
This quarter, Tigris will begin a dose-escalation, U.S. Phase I trial to evaluate GGTI-2418 in 25-40 patients. Tigris has exclusive, worldwide rights to the compound from the University of South Flori...